To include your compound in the COVID-19 Resource Center, submit it here.

Management tracks: Cheng joins Akero, bluebird COO leaving

Metabolic company Akero Therapeutics Inc. (Cambridge, Mass.) named former Gilead Sciences Inc. (NASDAQ:GILD) executive Andrew Cheng president and CEO. Cheng joined Gilead in 1999 to lead its development programs in HIV/AIDS and became an EVP in 2015. He was promoted to CMO

Read the full 424 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers